KCNK2: Potassium channel subfamily K member 2
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
K(+) channel that conducts voltage-dependent outward rectifying currents upon membrane depolarization.
- Drugs that act on it: 5
- Approved: 5
- In phases 1 to 3: 0
- Sponsors: 3
Who Is On It, and How Far Along
Every drug ChEMBL records acting on KCNK2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Baxter International360%
- AbbVie120%
- Pfizer120%
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule5100%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Potassium channel subfamily K member 2 opener.| Sevoflurane | Approved | AbbVie | Small molecule | Opener | — | 167 | — |
| Isoflurane | Approved | Baxter International | Small molecule | Opener | — | 31 | — |
| Desflurane | Approved | Baxter International | Small molecule | Opener | — | 28 | — |
| Enflurane | Approved | Baxter International | Small molecule | Opener | — | 0 | — |
| Halothane | Approved | Pfizer | Small molecule | Opener | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Abnormality of the skeletal system
- 0.43
- Hypertensive disorder
- 0.43
- Sedation
- 0.38
- Delirium
- 0.37
- Female reproductive system disorder
- 0.33
- Mitral valve disorder
- 0.32
- Aortic valve disorder
- 0.32
- Cleft palate
- 0.32
- Cleft lip
- 0.32
- Iron metabolism disease
- 0.30
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2321615, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt O95069, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets